Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro /GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) --

Focused on protecting and returning value of  Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.

Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio common stock owned First Tracks Bio initial cash balance of $180 million,